In this article, we will examine the 15 Best Biotech Stocks to Buy According to Wall Street Analysts.
The biotech sector has been a disaster for investors over the past five years going by a 14% decline compared to an 86% gain for the S&P 500 over the same period. Fast forward, sentiments and outlook have improved significantly over the past year. The S&P 500 Biotech index is up by 32% year to date, outperforming the overall market.
The prospects of further interest rate hikes are already giving investors optimism about a recovery in the sector. Interest rate cuts are the catalyst behind investors rushing back to riskier corners of the market with a focus on high-risk, high-reward opportunities in the biotechnology sector.
Clinical-stage biotech companies are among the biggest gambles in the market. That’s because companies burn through cash faster than they can raise it. Consequently, they tend to thrive whenever the US Federal Reserve cuts rates.
“With the potential for interest rates to be cut more, you’re going to see a loosening up, especially with the biotech sector sentiment getting slightly better,” said Hartaj Singh, founding partner of Tecumseh Partners.
Lower borrowing costs should be a boon for the biotechnology sector, as was the case during the pandemic, when the Fed cut rates to all-time lows.
“Usually the first three to six months of a rate cycle aren’t necessarily a positive for biotech stocks,” said Mike Perrone, a health-care specialist at Baird. But “this could be a little bit different because it feels like the economy’s in a better place than it usually is by the time we cut rates.”
Optimism that the President Donald Trump administration will ease regulations is another factor fuelling sentiments around biotech stocks. With that in mind, let’s take a look at some of the best biotech stocks to buy according to Wall Street analysts.
Our Methodology
To compile the list of Best Biotech Stocks to Buy According to Wall Street Analysts, we used Finviz Screener to identify biotechnology stocks. We focused on stocks with an upside potential of more than 30% (as of December 10) and detailed the number of hedge funds holding stakes in them in the third quarter of 2025. Finally, we ranked the stocks in ascending order based on their upside potential.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research shows we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
Best Biotech Stocks to Buy According to Wall Street Analysts
15. Disc Medicine, Inc. (NASDAQ:IRON)
Stock Upside Potential: 31.24%
Number of Hedge Fund Holders: 34
Disc Medicine Inc. (NASDAQ: IRON) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Leerink Partners raised its price target of the stock to $115 from $110 while reiterating an Outperform rating.
The price target hike comes after the US Food and Drug Administration accepted the company’s New Drug Application for its lead asset, bitopertin, an oral GlyT-1 inhibitor for erythropoietic protoporphyria (EPP). The company posted topline interim data in the Phase 2 RALLYMF trial in patients with myelofibrosis anemia. The research firm remains confident in the candidate drug’s prospects, with a high probability of success for DISC-0974 in myelofibrosis. Consequently, it has raised the company’s revenue forecast to about $748 million from $359 million.
Analysts at Raymond James have also echoed similar sentiments on raising the stock’s price target to $117 from $108 while reiterating a Strong Buy rating. The price target hike is in response to topline interim data from the RALLY-MF Phase 2 trial in patients with Myelofibrosis (MF) and Anemia presented at ASH 2025.
Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biopharmaceutical company focused on creating new treatments for serious blood (hematologic) diseases by targeting red blood cell biology, specifically heme production and iron balance.
14. Caris Life Sciences, Inc. (NASDAQ:CAI)
Stock Upside Potential: 41.18%
Number of Hedge Fund Holders: 32
Caris Life Sciences Inc. (NASDAQ:CAI) is one of the best biotech stocks to buy according to Wall Street analysts. On December 4, 2025, Caris Life Sciences (NASDAQ:CAI) announced it will present 19 breast cancer studies at the San Antonio Breast Cancer Symposium, conducted with more than 40 partner institutions through the Caris Precision Oncology Alliance. Spanning seven disease subtypes, the work showcases how Caris’ multi-omic tumor profiling, AI-driven signatures, and biomarker discovery improve recurrence prediction, risk stratification, and outcomes. Executives highlighted the company’s leadership in integrating exome and transcriptome sequencing with IHC profiling, with two studies chosen for oral presentation underscoring its advances in personalized cancer care.
Earlier on December 2, analysts at Cannaccord Genuity initiated coverage of the stock with a Hold rating and a $28 price target. The company remains in a strong position in the precision oncology market, owing to its differentiated multi-modal platform and early momentum in tissue and blood-based therapy selection.
Likewise, the company’s dual-modality infrastructure and robust data assets also affirm its prospects in oncology, backed by an expanding artificial intelligence suite. Consequently, the company posted a 113% increase in Q3 revenue to $216.8 million. It also posted a positive adjusted EBITDA of $51.2 million, affirming improved operational efficiency.
Caris Life Sciences, Inc. (NASDAQ:CAI) is a precision medicine company focused on oncology that offers advanced tumor profiling to help doctors personalize cancer treatment by analyzing a tumor’s unique molecular signature to guide therapy, find clinical trials, and predict drug effectiveness.
13. Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
Stock Upside Potential: 42.97%
Number of Hedge Fund Holders: 42
Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Baird reiterated its Outperform rating on Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) and raised the price target to $88 from $80.
The price target hike follows the company’s agreement to acquire Bluejay Therapeutics for $620 million in cash. With the acquisition, the company gains worldwide rights to brelovitug, a monoclonal antibody under development for the treatment of chronic hepatitis D, a rare and aggressive liver condition.
“This acquisition fits squarely with what we do best—advancing high-impact medicines for patients with rare diseases through disciplined development, regulatory innovation, and commercial excellence,” Mirum CEO Chris Peetz said in the release.
The acquisition of Brelovitug comes on the heels of 100% HDV RNA response in Phase 2 clinical trials, with Phase 3 results expected in the second half of next year.
Analysts at Morgan Stanley have also reiterated an Overweight rating on Mirum Pharmaceuticals with an $81 price target. The investment bank views the deal as a smart strategic move for Mirum, saying it bolsters the company’s position in rare liver diseases while offering clear synergies with its current commercial setup. The firm also projects that the enlarged pipeline could generate more than $4 billion in peak sales.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)is a biopharmaceutical company focused on developing and delivering treatments for rare and debilitating liver diseases, especially those affecting children, by transforming scientific discoveries into therapies such as their key drug LIVMARLI (maralixibat) for cholestatic pruritus in Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC).
12. BioNTech SE (NASDAQ:BNTX)
Stock Upside Potential: 43.16%
Number of Hedge Fund Holders: 24
BioNTech SE (NASDAQ:BNTX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Clear Street analysts reiterated a Buy rating on BioNTech SE (NASDAQ:BNTX), buoyed by top-line results on one of the company’s experimental treatments.
Gotistobart is the company’s anti-CTLA4 therapy in second-line or later squamous non-small cell lung cancer (NSCLC), showing tremendous potential. Immediate data shows the therapy reduces death risk by 54% compared to standard chemotherapy. It also boasts a 63% survival rate versus 30% with chemotherapy.
Clear Street remains optimistic that Gotistobart will provide a chemotherapy-free alternative with extended survival benefits for NSCLC patients progressing on PD-L1 inhibitors. Likewise, the research believes the company’s oncology pipeline remains undervalued given its potential to be combined with in-house antibody-drug conjugates.
BioNTech SE (NASDAQ:BNTX) is a German biotechnology company that develops and commercializes novel immunotherapies and vaccines for cancer and infectious diseases. It is widely recognized for creating the first approved mRNA-based drug, the Pfizer-BioNTech COVID-19 vaccine, sold under the brand name Comirnaty.
11. Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Stock Upside Potential: 47.34%
Number of Hedge Fund Holders: 44
Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, H.C. Wainwright reiterated a Buy rating on Ocular Therapeutix Inc. (NASDAQ:OCUL) and raised the price target to $21 from $19.
The research firm remains confident about the company’s outlook following the submission of a new drug application for AXPAXLI, its 450 µg axitinib intravitreal implant. The company has already received a boost from FDA commissioner Marty Makary, who reiterated that the agency will only require one pivotal clinical trial instead of two for new drug approvals.
Ocular Therapeutics is on course to deliver topline results in the first quarter of next year in its Phase 3 SOL-1 trial. It plans to leverage the 505(b)(2) regulatory pathway, which is expected to shorten the review timeline for its candidate drug, AXPAXLI.
“At Ocular Therapeutix, we have always been courageous, opportunistic, and bold in our efforts to redefine retina,” said Pravin U. Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix. “Based on recent developments, we now intend to submit our NDA for AXPAXLI in wet AMD shortly after SOL-1 year one data, assuming positive results.”
Ocular Therapeutix Inc. (NASDAQ:OCUL) is a biopharma company that develops, manufactures, and sells innovative eye treatments for serious eye diseases, using its proprietary hydrogel technology to deliver drugs directly to the eye, reducing the need for frequent drops and improving outcomes for conditions like wet AMD, glaucoma, and post-surgery pain/inflammation.
10. Praxis Precision Medicines Inc. (NASDAQ:PRAX)
Stock Upside Potential: 49.20%
Number of Hedge Fund Holders: 33
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Praxis Precision Medicines Inc. (NASDAQ:PRAX) affirmed successful completion of a pre-New Drug Application meeting with the US Food and Drug Administration for Ulixacaltamide, its investigational oral drug for essential tremor (ET). The company hopes to submit a New Drug Application early next year.
The company also confirmed positive results from the EMBOLD study evaluating riluzole for patients with SCN2A- and SCN8A-related developmental and epileptic encephalopathies (DEEs). The positive results included a 53% placebo-adjusted reduction in seizures and no serious adverse events.
Meanwhile, analysts at TD Cowen have reiterated a Buy rating on the stock and increased the price target to $353 from $251. Praxis presented updated Phase 2 RADIANT trial data at AES 2025 showing its candidate vormatrigine achieved nearly 100% median seizure reduction in focal onset seizures and about 80% in generalized epilepsy, while interim EMBOLD results revealed relutrigine delivered a 53% placebo-adjusted reduction with continued benefits in the open-label extension; following these findings, TD Cowen raised its price target on Praxis to $353, reflecting confidence in the company’s epilepsy pipeline.
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is a clinical-stage biotech company developing targeted therapies for severe brain disorders like epilepsy, depression, and movement disorders.
9. Arcellx, Inc. (NASDAQ:ACLX)
Stock Upside Potential: 59.84%
Number of Hedge Fund Holders: 36
Arcellx Inc. (NASDAQ:ACLX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, the company delivered promising Pivotal Phase 2 study results of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma. The company is developing an anti-CD in partnership with Kite, a Gilead company unit, ahead of the planned 2026 commercial launch.
The trial results from the iMMagine-1 study underlined deep and durable responses with a predictable and manageable safety profile. No adverse effects such as Parkinsonism, cranial nerve palsies, or Guillain-Barré syndrome have been observed with anti-cello as part of the ongoing trials.
“These data are compelling and are an important advancement for patients living with multiple myeloma,” said Dr. Krina Patel, Associate Professor at the Department of Lymphoma/Myeloma, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, and iMMagine-1 and iMMagine-3 clinical investigator.
Stifel has reiterated a Buy rating and a $127 price target, impressed by initial data from the Phase 3 MajesTEC-3 TRIAL. The results showed landmark progression-free survival and overall survival rates.
Arcellx, Inc. (NASDAQ:ACLX) is a clinical-stage biotech company developing innovative cell therapies for cancer and autoimmune diseases, using proprietary D-Domain technology (ddCAR) and the ARC-SparX platform to create safer, more controllable, and broadly accessible treatments, with a key focus on multiple myeloma and leukemia.
8. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Stock Upside Potential: 61.13%
Number of Hedge Fund Holders: 54
Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best biotech stocks to buy according to Wall Street analysts. On November 18, BioMarin Pharmaceutical (NASDAQ:BMRN) presented at the Jefferies London Healthcare Conference, where CEO Alexander outlined progress on the company’s $500 million cost transformation program, now about two-thirds complete, and announced a goal of reaching a 40% non-GAAP operating margin next year, up from 19% in 2023.
He said BioMarin is concentrating on genetically defined conditions with few competitors, pointing to the continued global rollout of Voxogo, now available in 55 countries, and the ongoing growth of more than 20% a year for Palynziq. He also highlighted progress on BMN 351 for Duchenne muscular dystrophy and the upcoming Phase 3 readouts for hypochondroplasia and Voxogo. While noting lingering regulatory and competitive pressures, Alexander stressed that the company remains focused on innovation, speeding up development of its pipeline, and creating value for shareholders.
Meanwhile, on December 3, analysts at Leerink Partners downgraded the stock to a Market Perform from Outperform and cut the price target to $60 from $82. Despite the downgrade, the research firm echoed the company’s restructuring drive that entails labor force reduction, pipeline reorganization, and the discontinuation of the Roctavian program. The research firm has also echoed the acquisition of Inozyme, expected to drive future growth.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a global biotech company focused on developing and commercializing therapies for severe, life-threatening rare genetic diseases by leveraging genetics to create transformative treatments.
7. Corcept Therapeutics Incorporated (NASDAQ:CORT)
Stock Upside Potential: 63.09%
Number of Hedge Fund Holders: 28
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best biotech stocks to buy according to Wall Street analysts. On November 25, H.C. Wainwright reiterated a Buy rating and a $145 price target on the stock, citing its strong growth prospects despite commercial challenges.
The research firm has reiterated its confidence in the company’s Korlym medication, whose sales are projected to grow by 19% to 26% year over year, affirming the underlying strong demand. Volume has increased by 40% over the past two quarters, and the company is poised to meet its guidance of $800-$850 million.
Likewise, Corcept is a Buy owing to a strong balance sheet that supports the launch of two products next year. The company is on the cusp of launching relacorilant for Cushing’s syndrome, with sales expected to reach $4.3 billion by 2034.
On November 17, Wolfe Research began coverage of Corcept Therapeutics (NASDAQ: CORT) with a Peer Perform rating and said it expects the stock to trade in the $70- $75 range until the company’s patent litigation and antitrust cases are settled. Analyst Kalpit Patel pointed to these legal issues as near-term hurdles but also noted the potential boost from relacorilant, which has a PDUFA date for hypercortisolism on December 30, 2025. Although the firm sees promise in the drug, Wolfe Research remains more cautious on its peak sales outlook than the broader market.
Corcept Therapeutics Incorporated (NASDAQ:CORT) develops drugs that modulate the stress hormone cortisol to treat severe metabolic, oncologic (cancer), and neuropsychiatric disorders, with their first approved drug, Korlym, treating Cushing’s Syndrome, and their pipeline exploring treatments for cancers, ALS, and liver diseases.
6. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Stock Upside Potential: 67.01%
Number of Hedge Fund Holders: 31
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Piper Sandler reiterated that Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the stocks to own as the company is poised for transformational growth in 2026.
According to the research firm, the company is staring at tremendous opportunities and a transformational year as it launches key drugs. The remarks follow confirmation of dosing the first patient in Phase ½ of a study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin receptor type 2 (SST2)-positive neuroendocrine tumors.
The BRAVESST2 study seeks to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CRN09682 from the nonpeptide drug conjugate (NDC) platform. Crinetics is in a strong financial position, with more cash than debt on the balance sheet, enabling it to accelerate pipeline development.
“We developed CRN09682 to address the need for a more efficacious, safer, and convenient targeted therapy for patients with SST2-expressing tumors,” said Stephen Betz, Chief Scientific Officer and Co-Founder of Crinetics, in the press release.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a clinical-stage drug company focused on developing oral treatments for rare endocrine (hormonal) diseases and tumors, including acromegaly, Cushing’s disease, carcinoid syndrome, and congenital adrenal hyperplasia (CAH), using small molecules and peptide agonists that target hormone receptors.
5. Vaxcyte, Inc. (NASDAQ:PCVX)
Stock Upside Potential: 95.63%
Number of Hedge Fund Holders: 46
Vaxcyte Inc. (NASDAQ: PCVX) is one of the best biotech stocks to buy, according to Wall Street analysts. On December 8, the company confirmed the dosing of the first patients in its Phase 3 OPUS trial. The company is evaluating VAX-31 in the prevention of invasive pneumococcal disease and pneumonia in adults. It plans to enroll 4,000 participants in consultation with the US Food and Drug Administration.
Topline safety and tolerability results from the trial should serve as the basis for VAX-31 Biologics License Application in the fourth quarter of next year. The company is building on VAX-31 Phase ½ studies that showed both broader serotype coverage and stronger overall immune responses than Prevnar 20 (PCV20).
“On the strength of the unprecedented results from our VAX-31 Phase 1/2 study in adults and our carrier-sparing platform, we are uniquely positioned to set a new standard by which future adult pneumococcal vaccines will be measured. Through this program, we are aiming to expand the breadth of disease and serotype coverage while ensuring immunogenicity levels remain high to ensure durable protection,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.
On November 19, analysts at Leerink Partners raised the stock’s price target to $77 from $60 while reiterating an Outperform rating. The positive stance echoes the research firm’s confidence about the company’s optimized VAX-31 pneumococcal conjugate vaccine dose. With GSK and Pfizer disclosing issues with their pneumococcal conjugate vaccine programs, the research firm sees tremendous market potential for VAX-31.
Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage vaccine company focused on developing vaccines to combat serious bacterial infections like pneumococcal disease, Group A Strep, and Shigella. It leverages advanced cell-free technology to create complex proteins for better immune responses, with key candidates like VAX-31 and VAX-24 in advanced clinical trials for infants and adults.
4. Summit Therapeutics Inc. (NASDAQ:SMMT)
Stock Upside Potential: 109.34%
Number of Hedge Fund Holders: 27
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best biotech stocks to buy according to Wall Street analysts. On December 4, Citi analyst Yigal Nochomovitz reiterated a Buy rating on Summit Therapeutics Inc. (NASDAQ:SMMT) and set a $131.90 price target.
The positive stance follows the Jefferies London Healthcare Conference 2025, during which the company showcased its strategic advancements, including the development of ivonescimab, a novel PD-1/VEGF bispecific antibody. Ivonescimab has already been given to more than 3,000 patients in clinical trials and over 40,000 patients in both commercial and clinical settings, including in China, demonstrating its widespread use.
The Harmony 3 study continues to move forward, with pivotal readouts expected in 2026 and 2027, and a BLA filing for EGFR second-line therapy planned this quarter. Early clinical data have been encouraging. The Harmoni 6 trial reported a hazard ratio of 0.60, a 40% improvement versus standard care in squamous NSCLC, while updated Harmony A results showed an overall survival hazard ratio of 0.74. The squamous cohort of Harmony 3 is more than 80% enrolled and should finish in the first half of 2026, with the non-squamous cohort expected to complete later that year.
Summit has also started a new colorectal cancer study, and its partnership with Revolution Medicine aims to combine ivonescimab with RAS inhibitors, with patient dosing expected to begin early next year. PFS and interim survival readouts planned for 2026 could further support ivonescimab’s potential role in cancer treatment.
With more than $750M in cash from recent financing, the company says it has enough capital to support operations and key milestones for the next 12 to 18 months.
Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company developing treatments for serious unmet medical needs, primarily in oncology, with its lead drug, ivonescimab, a bispecific antibody.
3. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Stock Upside Potential: 111.65%
Number of Hedge Fund Holders: 55
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best biotech stocks to buy according to Wall Street analysts. On December 4, Citi analyst Yigal Nochomovitz reiterated a Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and set a $103 price target. The positive stance aligns with a Consensus Strong Buy rating from 13 Wall Street analysts, comprising 12 Buys and 1 Hold.
The average price target on Ultragenyx Pharmaceutical is $76.83, implying 111.65% upside potential from current levels of $36.30. On November 21, Cantor Fitzgerald reaffirmed its Overweight rating and $105 price target on Ultragenyx Pharmaceutical following third-quarter 2025 results and recent financial actions. Ultragenyx, which focuses on rare and ultra-rare genetic diseases, announced on November 4 the sale of an additional portion of future royalty interest in Crysvita, one of its key commercial products. Cantor noted that while the deal strengthens liquidity, it does not alter the firm’s overall valuation view of the company.
Ultragenyx reported Q3 revenue of $160 million, below the consensus of $167 million, and EPS of -1.81 versus the expected -1.23. Despite the shortfalls, the company confirmed its full-year revenue guidance of $640 to $670 million. To further support its financial position, Ultragenyx sold 25% of its North American Crysvita economics, receiving $400 million upfront from OMERS. Cantor Fitzgerald adjusted its model to account for these moves but maintained confidence in Ultragenyx’s long-term growth, highlighting the company’s strategic focus on rare disease therapies and its ability to use Crysvita royalties to advance the pipeline and create shareholder value.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is a biopharmaceutical company focused on developing and commercializing treatments for severe, debilitating, rare, and ultra-rare genetic diseases, using modalities like biologics, gene therapies, and ASOs to address high unmet medical needs.
2. Viking Therapeutics, Inc. (NASDAQ:VKTX)
Stock Upside Potential: 160.92%
Number of Hedge Fund Holders: 37
Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best biotech stocks to buy according to Wall Street analysts. On November 20, H.C. Wainwright reaffirmed its Buy rating and $102 price target on Viking Therapeutics, Inc. (NASDAQ:VKTX) after the company finished enrollment ahead of schedule in its Phase 3 VANQUISH-1 obesity study, bringing in 4,650 adults instead of the planned 4,500. The trial includes people with obesity or overweight and related health conditions, marking an important step forward for Viking’s pipeline.
The VANQUISH 2 study, which is enrolling 1,100 adults with type 2 diabetes who are also obese or overweight, is expected to complete enrollment in early 2026. Both trials are evaluating weekly injections of VK2735 at several dose levels compared with placebo, with the primary goal being percent weight change at week 78. Additional measures include weight-loss milestones and safety results, and participants receiving VK2735 can continue treatment in an open-label extension.
At the Jefferies London Healthcare Conference 2025 on November 19, Viking Therapeutics reiterated that it is making significant progress in developing its pipeline, including VK2735, an obesity treatment. The company is advancing the obesity candidate drug into Phase III trials for a subcutaneous formulation, following topline Phase II results showing up to 12.2% weight loss.
The company’s Amylin agonist program is advancing into clinical trials, with plans to file an IND next year. The company exited the third quarter with $700 million in cash reserves sufficient to accelerate the pipeline development.
Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharma company developing treatments for metabolic and endocrine diseases like obesity, fatty liver (MASH/NAFLD), and rare conditions like X-ALD, primarily using small-molecule drugs that target hormone receptors (like GLP-1/GIP, TRβ agonists) for weight loss, cholesterol, and liver fat reduction.
1. Legend Biotech Corporation (NASDAQ:LEGN)
Stock Upside Potential: 171.40%
Number of Hedge Fund Holders: 28
Legend Biotech Corp (NASDAQ:LEGN) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, RBC Capital reiterated an Outperform rating on Legend Biotech Corp (NASDAQ:LEGN) and set a $74 price target.
The positive stance echoes the superior efficacy data on the company’s multiple myeloma treatment CARVYKTI. Data presented at the ASH conference showed the candidate drug achieved more than 50 months of media progression-free survival in patients, setting a very high bar compared to peers. CARVYKTI is currently approved for adults with relapsed or refractory multiple myeloma, having treated over 9,000 patients globally.
The investment firm insists the stock’s current share price discounts the company’s ability to maintain market share backed by a robust pipeline. Consequently, RBC Capital expects the company to continue enjoying strong growth and near-term profitability. That’s in part because the company has demonstrated impressive revenue growth of 74.75% over the past 12 months.
Legend Biotech Corporation (NASDAQ:LEGN) is a global, clinical-stage biotechnology company that develops and commercializes advanced cell therapies, primarily for cancer, using technologies such as CAR-T cells, gamma-delta T cells, and NK cells to create treatments for life-threatening diseases, with notable success in multiple myeloma treatment via CARVYKTI in partnership with Johnson & Johnson.
While we acknowledge the potential of Legend Biotech Corporation (NASDAQ:LEGN) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LEGN and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 9 Cheap Oil Stocks Under $10 to Buy Now and 9 Best EV Charging Stocks to Buy Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
